Actitrexx raises €5.4M Seed round

13 March 2021· Mainz, Germany· health, biotech, cell_therapy, b2b, deep_hardware

This funding was awarded as part of the GO-Bio Phase II program to support the company's official launch and the clinical development of its cell therapeutics for treating transplant rejection.

Investors

LeadGerman Federal Ministry of Education and Research

About Actitrexx

Stage
Seed
Headquarters
Mainz, Germany
Founded
2020
Team Size
6–20
Sectors
healthbiotechcell_therapyb2bdeep_hardware

Source: https://www.go-bio.de/de/aktuelles/nachrichten/actitrexx-sichert-sich-finanzierung-neue-therapie-gegen-transplantatabstossung.html